Fundz

Dialybrid secures €15 million in a Series A round led by XGEN Venture to fund the development of its Silkothane® Arteriovenous Graft for hemodialysis.

PRIVATESep 22, 2026

Amount Raised

€15 Million

Round Type

Series A

LombardyBiotechnologyHealth CareMedicalMedical Device

Investors

CDP Venture CapitalXGEN Venture

Description

Dialybrid S.r.l. has closed a €15 million Series A round aimed at advancing its innovative Silkothane® Arteriovenous Graft for vascular access in hemodialysis. Led by XGEN Venture, with participation from CDP Venture Capital, this funding will support both clinical and preclinical developments. The first-in-human clinical trial has commenced successfully

Quick answer

Dialybrid raised €15 Million in a Series A round, dated September 22, 2026. Investors: CDP Venture Capital and XGEN Venture. Dialybrid is based in Lombardy, Italy.

How much did Dialybrid raise?
Dialybrid raised €15 Million in a Series A round on September 22, 2026.
Who invested in Dialybrid?
CDP Venture Capital and XGEN Venture are named as investors in this round.
What does Dialybrid do?
Dialybrid S.r.l. is a privately held medical device company developing a novel vascular access solution for hemodialysis based on Silkothane®, a patented hybrid material made up of silk fibroin and polyurethane.
Where is Dialybrid based and how big is it?
Dialybrid is based in Lombardy, Italy. Fundz records about 7 employees.

Source: Fundz verified event record.

Who to call at Dialybrid, and when

A new round usually means Dialybrid is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Dialybrid raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Dialybrid, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Dialybrid. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Dialybrid

Location

Lombardy, Italy

About

Dialybrid S.r.l. is a privately held medical device company developing a novel vascular access solution for hemodialysis based on Silkothane®, a patented hybrid material made up of silk fibroin and polyurethane. The company focuses on addressing unmet clinical needs in vascular access for hemodialysis with innovative solutions. Their Silkothane® Arteriovenous Graft aims to improve patient outcomes and redefine standards of care. Dialybrid is advancing its product through clinical trials for regulatory approval.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Dialybrid raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Dialybrid's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Dialybrid raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.